Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial-Reference-Cited by-同舟云学术

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Published:2021-11 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lu Shun^ORCID,Wang Qiming,Zhang Guojun,Dong Xiaorong,Yang Cheng-Ta,Song Yong,Chang Gee-Chen,Lu You,Pan Hongming,Chiu Chao-Hua,Wang Zhehai,Feng Jifeng,Zhou Jianying,Xu Xingxiang,Guo Renhua,Chen Jianhua,Yang Haihua,Chen Yuan,Yu Zhuang,Shiah Her-Shyong,Wang Chin-Chou,Yang Nong,Fang Jian,Wang Ping,Wang Kai,Hu Yanping,He Jianxing,Wang Ziping,Shi Jianhua,Chen Shaoshui,Wu Qiong,Sun Changan,Li Chuan,Wei Hongying,Cheng Ying,Su Wu-Chou,Hsia Te-Chun,Cui Jiuwei,Sun Yuping,Ou Sai-Hong Ignatius,Zhu Viola W.,Chih-Hsin Yang James

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. EGFR T790M: revealing the secrets of a gatekeeper;Ko;Lung Cancer (Auckl),2017

2. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component;Yang;J Clin Oncol,2017

3. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study;Goss;Lancet Oncol,2016

4. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

5. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study;Frontiers in Pharmacology;2024-09-06

2. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial;Lung Cancer;2024-09

3. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10

4. Neoadjuvant aumolertinib monotherapy for EGFR-mutant lung squamous cell carcinoma: a case report;Translational Lung Cancer Research;2024-06

5. Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments;Translational Lung Cancer Research;2024-06